🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

37 results for “MDS” Clear

  1. A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms

    Incyte

    Treatment of participants with MF, MDS, ET, or MDS/MPN

    phase 1 other active

    1 trial

  2. A Phase I Study of BMS-986497 alone or in combination with Azacitidine (Aza) and Azacitidine plus Venetoclax (AZA+VEN) in relapsed or refractory (R/R) AML or MDS

    Bristol-Myers Squibb Australia Pty Ltd

    Acute Myeloid Leukemia and Myelodysplastic Syndrome

    phase 1 other active

    1 trial

  3. A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)

    AbbVie Deutschland GmbH & Co. KG

    Myelodysplastic Syndromes (MDS)

    phase 1 other active

    1 trial

  4. APR-548 + Azacitidine

    Aprea Therapeutics

    MDS

    phase 1 small molecule terminated

    1 trial

  5. ASTX727, ASTX727, Decitabine, ASTX727

    Taiho Pharma Netherlands B.V.

    Myelodysplastic Syndromes (MDS)

    phase 1 small molecule active

    1 trial

  6. Cardiac safety of treosulfan chemotherapy prior to stem cell transplantation in patients with leukemia.

    Medac Gesellschaft fuer klinische Spezialpraeparate mbH

    Subjects with AML ( Acute myeloid leukaemia) or MDS (Myelodysplastic syndrome) undergoing allogeneic hematopoietic stem cell transplantation

    phase 1 other active

    1 trial

  7. First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS)

    Genmab A/S

    Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome

    phase 1 other active

    1 trial

  8. Humanized anti-CD117 Monoclonal Antibody (JSP191)

    Jasper Therapeutics

    MYELODYSPLASTIC SYNDROME; MDS

    phase 1 mab active

    1 trial

  9. LGH447

    Novartis Pharmaceuticals

    AML and High Risk MDS

    phase 1 small molecule completed

    1 trial

  10. SENTI-202

    Essential Pharma Limited

    AML/MDS

    phase 1 mab active

    1 trial

  11. Safety of TEG001 in patients with r/r AML/high-risk MDS or r/r MM

    Disc Medicine

    Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Multiple Myeloma (MM)

    phase 1 other active

    1 trial

  12. Study to Evaluate the PK and Safety of Oral Decitabine and Cedazuridine in Cancer Patients with Hepatic Impairment

    Taiho Pharma Netherlands B.V.

    Solid tumor, Acute myeloid lymphoma (AML), Myelodysplastic syndrome (MDS)

    phase 1 other active

    1 trial

  13. Study to Evaluate the PK and Safety of Oral Decitabine and Cedazuridine in Cancer Patients with Renal Impairment

    Taiho Pharma Netherlands B.V.

    Acute myeloid lymphoma (AML), myelodysplastic syndrome (MDS), or solid tumors

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources